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Abstract
Background—Cervical cancer screening efforts linked to HIV/ AIDS care programs are being 
expanded across sub-Saharan Africa. Evidence on the age distribution and determinants of 
invasive cervical cancer (ICC) cases detected in such programs is limited.
Methods—We analyzed program operations data from the Cervical Cancer Prevention Program 
in Zambia, the largest public sector programs of its kind in sub-Saharan Africa. We examined age 
distribution patterns by HIV serostatus of histologically confirmed ICC cases and used 
multivariable logistic regression to evaluate independent risk factors for ICC among younger (≤35 
years) and older (>35 years) women.
Results—Between January 2006 and April 2010, of 48,626 women undergoing screening, 571 
(1.2%) were diagnosed with ICC, including 262 (46%) HIV seropositive (median age: 35 years), 
131 (23%) HIV seronegative (median age: 40 years), and 178 (31%) of unknown HIV serostatus 
(median age: 38 years). Among younger (≤35 years) women, being HIV seropositive was 
associated with a 4-fold higher risk of ICC [adjusted odds ratio = 4.1 (95% confidence interval: 
2.8, 5.9)] than being HIV seronegative. The risk of ICC increased with increasing age among 
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HIV-seronegative women and women with unknown HIV serostatus, but among HIV-seropositive 
women, the risk peaked around age 35 and non-significantly declined with increasing ages. Other 
factors related to ICC included being married (vs. being unmarried/widowed) in both younger and 
older women, and with having 2+ (vs. ≤1) lifetime sexual partners among younger women.
Conclusions—HIV infection seems to have increased the risk of cervical cancer among younger 
women in Zambia, pointing to the urgent need for expanding targeted screening interventions.
Keywords
invasive cervical cancer; HIV; risk; Zambia; women
Introduction
Invasive cervical cancer (ICC) is one of the commonest malignancies among women 
worldwide.1 In the developing world, it is the leading cause of new cancer cases and related 
deaths. Over 80% of the 270,000 deaths occur in the developing world.1–3 Of all estimated 
new cases of female cancers that occur in the sub-Saharan Africa, 22% are due to cervical 
cancer.4 In Zambia, ICC is the commonest cancer among women, and ICC incidence and 
mortality rates in Zambia are among the highest in the world.1,5,6
AIDS-associated malignancies such as cervical cancer are increasing in Zambia and other 
sub-Saharan African countries with high burdens of HIV, as increasing numbers of HIV-
infected women live longer as a result of access to antiretroviral therapy (ART).7,8 In 
general, HIV-infected women are at much higher risk for the incidence, progression, and 
persistence of carcinogenic human papillomavirus infection, the obligate cause of ICC.9–11 
It has been reported from previous smaller and retrospective studies from sub-Saharan 
Africa that HIV-seropositive women typically present with ICC at an earlier age.12–15 This 
likely results from a more rapid progression of chronic persistent human papillomavirus 
infection in this subpopulation, modulated by a relative immunosuppressive state (even 
while accessing ART),16,17 and is further accentuated by the limited or nonexistent access to 
cervical cancer screening services.
Apart from having one of the highest global incidence rates for cervical cancer, Zambia has 
a high HIV prevalence (14.3%).18 In response to the high burden of both HIV/ AIDS and 
cervical cancer, the Cervical Cancer Prevention Program in Zambia (CCPPZ) was initiated 
in January 2006, within an existing clinical platform developed through HIV/ AIDS care and 
treatment clinics. CCPPZ is a public sector initiative for provision of “screen and treat” 
cervical cancer prevention services in a setting-appropriate protocol and has screened over 
180,000 women over the past 8 years. With availability of large numbers of 
histopathologically-proven ICC cases detected and confirmed through population-based 
screening, the CCPPZ medical records database provides unique opportunities to undertake 
epidemiologic studies related to ICC and predisposing risk factors, especially in the context 
of high background HIV prevalence. In this article, we report results of an observational 
study focused on evaluating risk factors for ICC stratified by age [younger (≤35 years) and 
older women (>35 years)] among women screened in the program.
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Previous publications have described the program's implementation and operations.19–24 
Briefly, cervical cancer prevention services were offered within government-operated public 
sector clinics in which trained female Zambian nurses performed screening using visual 
inspection with acetic acid (VIA) aided by enhanced digital imaging of the cervix (digital 
cervicography) with a commercial-brand camera. Same-day treatment by cryotherapy was 
offered to eligible VIA-positive women, and those ineligible for cryotherapy were referred 
to an outpatient Gynecologic Cancer Prevention Clinic at the University Teaching Hospital 
(UTH) for histopathological evaluation by cervical punch biopsy or loop electrosurgical 
excision procedure (LEEP). Participant clinical and demographic information was entered 
electronically, at the point of care, into a database by community health workers and nurses 
and was updated weekly. Women attending CCPPZ clinics were asked to self-report HIV 
serostatus, although most HIV-seropositive women were “linked” to the HIV/AIDS care and 
treatment clinics co-located and operational in the same premises. Women testing HIV 
seronegative and women never tested for HIV were provided an on-site HIV test by CCPPZ 
nurses.
We analyzed deidentified baseline screening records and operations data and pathology 
reports with a diagnosis of ICC, regardless of stage of disease. We plotted age distribution 
curves stratified by HIV serostatus (HIV seropositive, HIV seronegative, and women whose 
HIV serostatus was unknown) and reported the median age at diagnosis for each group. We 
evaluated sociodemographic and clinical covariates (selected a priori) related to risk of ICC. 
Since the risk of ICC is directly linked with age, we sought to describe the probability of 
ICC stratified by younger (≤35 years) and older (>35 years) age groups. We evaluated the 
risk of ICC associated with each covariate using logistic regression and estimated crude and 
covariate-adjusted effects. We also tested the interaction of HIV and age by pooling the 
younger and older women in a single multivariable model. To account for possible nonlinear 
associations, continuous variables were included in the models using restricted cubic 
splines.25 Since not all women who were referred for histopathology actually underwent 
LEEP or had histopathology results, missing values of ICC status and baseline predictors 
were accounted for using multiple imputation techniques.26 In this technique, we modeled 
the probability of ICC among those patients referred to UTH, and using this model, we 
imputed ICC status for women who did not follow-up or have histopathology results. 
Women with negative screens were assumed to be ICC negative. For all women, we used 
other baseline characteristics to predict the missing value of covariates, and then, we 
performed regression on the imputed data. We repeated this technique 10 times and took the 
average estimates from multiple logistic regressions and computed confidence intervals 
(CIs) properly incorporating imputation uncertainty. Multiple imputation makes it less likely 
that ICC prevalence was underestimated and yields better power than casewise deletion for 
missing data. We also modeled the probability of ICC by HIV serostatus and age using 
restricted cubic splines. Baseline characteristics of those aged ≤35 and over 35 years were 
compared using rank-sum and χ2 tests. R-software 2.11.1 (www.r-project.org) was used for 
data analyses (note: analysis scripts are available at http://biostat.mc.vanderbilt.edu/
ArchivedAnalyses). This outcome evaluation study of anonymized patient records of a 
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public sector implementation program was deemed exempt from human subjects review or 
the need for informed consent by the Research Ethics Committee of the University of 
Zambia.
Results
Characteristics of Screened Population
Between January 2006 and April 2011, 56,427 women were evaluated in the program, of 
which 55,630 had age information. Of these, a total of 48,626 had verifiable information on 
their screening status and formed the denominator for this analysis (see Supplemental 
Digital Content 1, http://links.lww.com/QAI/A688 for a flowchart of the screening program 
operations). The median age was 32 years (interquartile range, 26–39). Of this entire cohort, 
65% (31,578/48,626) were aged ≤35 years (Table 1). Less than half (42.7%) of the women 
screened had a high school education level or less, and a large majority (86.3%) were 
married and living together with spouses. The median age at sexual debut was 18 years 
(interquartile range, 16–19), just over half of the women (54.5%) earned less than Zambian 
Kwacha 500,000/day (approximately $100/month or $3/day, based on 2011 exchange rates) 
and a majority of women (64.5%) reported never using a condom with their regular partner. 
A total of 14,153 (29.1%) were HIV seropositive, 20,211 (41.6%) were HIV seronegative, 
while 14,262 (29.3%) had unknown HIV serostatus (Table 1).
Among 5010 women referred to UTH (see Supplemental Digital Content 1, http://
links.lww.com/QAI/A688), 2437 (48.6% of 5010) received confirmed histology results. For 
the rest, that is, 2573 (51.4% of 5010 women, which included 1551 who missed 
appointments at UTH and 1022 who did not get histopathology results), results were derived 
from multiple imputation techniques.
Characteristics of Women With ICC
Among the 2437 women with confirmed histology results, 571 (23.4%) were diagnosed with 
ICC. Among these 262 (46%) were HIV seropositive (median age: 35 years), 131 (23%) 
were HIV seronegative (median age: 40 years), and 178 (31%) had unknown HIV serostatus 
(median age: 38 years) (Fig. 1). Among the 571 women with ICC, 226 (39.6%) were ≤35 
years. In this group (≤35 years), women with ICC were more likely to be educated beyond 
high school (P = 0.01), report greater number of lifetime sexual partners (P < 0.001), have 
lower number of pregnancies (P < 0.001), have overall lower rates of condom use with 
regular partners (P < 0.001), and report being HIV seropositive (P < 0.001) compared with 
the women >35 years (Table 2). The data on stages at presentation available in 255/571 
women with ICC were as follows: stage IA: 46 (18%), stage IB: 70 (27%), stage IIA: 23 
(9%), stage IIB: 40 (16%), stage IIIA: 9 (4%), stage IIIB: 30 (12%), stage IVA: 6 (2%), and 
unstaged: 31 (12%). A greater proportion (48%) of cancers in HIV-seropositive women 
were early stage (IA/IB) as compared with HIV-seronegative women and women of HIV-
unknown serostatus (32% and 36%, respectively) (data not shown).
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Interaction of Age and HIV Serostatus
There was strong evidence of an interaction between HIV status and age group on the odds 
of ICC, overall (P < 0.001) and when restricted to the subset of women aged >35 years (P < 
0.01), but not among women aged #35 years (P = 0.3) (Fig. 2). The risk of ICC among HIV-
seropositive women peaked around age 35. Thereafter, among HIV-seropositive women, the 
odds of ICC stayed fairly constant with increasing age [adjusted odds ratio (aOR) = 0.94 per 
5 years (95% CI: 0.80 to 1.09); Table 4 footnote]. However, among women aged >35 years 
or older who were HIV seronegative or of unknown HIV status, the probability of ICC 
continued to increase with increasing age (aOR = 1.28; 95% CI: 1.14 to 1.43 for HIV-
seronegative woman, and aOR = 1.23; 95% CI: 1.13 to 1.34 for women with unknown HIV 
status; Table 4 footnote).
Determinants of ICC Risk in Women Aged ≤35 Years
Among 29,973 women aged ≤35 years, 226 (0.75%) were diagnosed with ICC. For every 5-
year increase in age, a woman had 68% higher odds of ICC [aOR = 1.7 (1.4–2.0), with every 
5-year increment in age]. Married women had twice the odds of ICC [aOR = 2.1 (1.2–3.5)] 
as compared with women who were not married. Women reporting 2+ lifetime sexual 
partners [aOR = 1.8 (1.4–2.4)] were more likely to be diagnosed with ICC. Being HIV 
seropositive [aOR = 4.1 (2.8–5.9)] or having an unknown HIV serostatus [aOR = 2.0 (1.3–
2.9)] was also independently associated with having ICC (Table 3).
Determinants of ICC Risk in Women Aged >35 Years
Among 16,080 women older than 35 years, 345 (2.1%) were diagnosed with ICC. In 
addition to the strong interaction between age and HIV serostatus, being married [aOR = 2.2 
(1.5–3.2)] was independently associated with ICC among women aged >35 years. To 
directly compare the association between HIV status and ICC between the younger vs. older 
age strata, we fit a simplified model that ignored the interaction between age and HIV 
serostatus among women aged >35 years (Table 4). The odds of ICC was 80% higher for an 
HIV-seropositive women than a seronegative woman (aOR = 1.8; 95% CI: 1.4 to 2.4); this 
odds ratio was statistically smaller than that observed in women ≤35 years (P < 0.01).
Discussion
Although ICC is a disease that typically develops among women in their 40s or 50s, we 
report a high burden of histologically confirmed ICC among women who are in their mid-
thirties and younger in Zambia. Our study highlights 3 prominent findings: first, the age 
distribution revealed a lower median age at diagnosis of ICC for HIV-seropositive women 
(35 years) vs. that for HIV-seronegative women (40 years), although the age distribution in 
the overall screened population suggested a higher median age for the HIV-seropositive vs. 
HIV-seronegative women (32 vs. 28 years, data not shown). Indeed, HIV-seropositive 
women constituted the majority (57.1%, 129/226) of women 35 years or younger who were 
diagnosed with ICC, although just over a quarter of women (26.2%, 8269/31,578) screened 
in this age group were HIV seropositive. Second, younger HIV-seropositive women had 4 
times higher odds of ICC than younger HIV-seronegative women, whereas among older 
women, this risk differential was just under 2-fold. Finally, the risk of ICC increased with 
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age for HIV-seronegative women, as has been seen in epidemiologic studies in the general 
population worldwide, but the pattern was markedly different in HIV-seropositive women. 
In this group, the risk peaked in the fourth decade of life and plateaued (with a 
nonsignificant decline) in subsequent decades. A possible explanation for this could be the 
effect of excess mortality due to HIV/AIDS among women in the older cohort before ART 
started becoming widely accessible in Zambia a decade ago.
Together, these results constitute the first demonstration in a “real world” population-based 
screening program of the impact of the HIV/AIDS epidemic on early age of ICC diagnosis 
in sub-Saharan Africa. Our study is one of the largest studies to evaluate the determinants of 
risk of histologically confirmed ICC, especially in younger women.12–14,27–30 Among other 
studies in Africa, a retrospective case–control study done in Uganda looking at how HIV 
affects the age of diagnosis of cervical cancer showed that HIV was associated with early 
onset of cervical cancer.27 A prospective observational study done in South Africa 
suggested that HIV speeds the change from preinvasive to invasive stage through a 
shortened preinvasive stage.12 The younger age of presentation of ICC among HIV-
seropositive women has been also reported in several smaller studies in sub-Saharan 
Africa.13–15,29,30 However, in a study done in Dakar, Senegal, an increase in ICC was noted 
only in women above the reproductive age, 55 years and above.28 This is perhaps due to the 
higher prevalence of HIV-2 in this population (compared with HIV-1, which is more 
prevalent in Southern Africa); since HIV-2 has a long latent period and slower progression 
to AIDS.
Other than HIV, a common independent predictor for ICC in both older and younger women 
was being married. The increased risk in married women points to the need for expanding 
targeted awareness messages and provision of cervical cancer screening services among 
married women in suitable clinical venues such as antenatal/postnatal clinics or family 
planning/reproductive health/well women clinics, including targeting awareness messages 
for husbands and other family members.
The strengths of this study includes the availability of a large electronic medical records 
database of screening history with key sociodemographic and sexual and reproductive 
history covariates, the linkages with histologically confirmed diagnoses of ICC, and the 
nesting of the screening implementation program within a public sector HIV/AIDS care 
infrastructure that allows the stratification by HIV serostatus. Nonetheless, there are some 
limitations of this effort as can be expected of an implementation science study that relies on 
the use of routine implementation data, as opposed to the more sanitized (but less 
representative) data available through stringently conducted observational studies or clinical 
trials. The VIA-based screening may have missed cancers among older postmenopausal 
women (in whom the squamocolumnar junction moves further into the endocervical canal, 
thereby increasing potential for missing a screen-detectable cancer). However, the use of 
enhanced digital imaging (digital cervicography) of the cervical transformation zone, 
coupled with the use of LEEP (as opposed to punch biopsy) for histologic confirmation of 
lesions that extend into the endocervical canal, helps to ensure that such cases are less likely 
to be missed. The self-reported nature of HIV serostatus, as also the respondent and social 
desirability bias when answering sexual history and behavioral questions, may have led to 
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some exposure misclassification, although this is likely nondifferential. Finally, although the 
cancer case confirmation was done among participants of a population-based screening 
program, it is possible that in the context of low resources where most women have not been 
screened, symptomatic women might have preferentially presented for care compared with 
asymptomatic women. It is unknown if such differences between younger and older women 
and by HIV status would differentially affect the results of the study.
In summary, our study illustrates the impact of HIV on rates of ICC among women in 
Zambia, particularly younger women. Our study strongly underlines the critical importance 
of instituting and expanding early detection and treatment services. The average age of first 
childbearing in Zambia is 18 years,31 and the age group of women under 35 years 
constitutes the majority of reproductive age women. The economic and social ramifications 
of cervical cancer-related disabilities and premature deaths are catastrophic for families, 
especially orphaned children, and ultimately destabilizing the larger society. Considering 
that each case of ICC was preventable many years prior, each such death calls into action an 
urgent need to undertake massive expansion of cervical cancer screening services for 
women across these resource constrained settings, including and especially for those among 
them who are younger and HIV infected.
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Histograms of the ages at diagnosis of ICC stratified by HIV serostatus among women 
screened in the CCPPZ.
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Probability of ICC by age and HIV serostatus among women screened in the CCPPZ. 
Predicted probability curves and 95% confidence intervals are shown for women with HIV 
seropositive, HIV seronegative, and serostatus unknown. Small histograms are overlaid in 
the top panel to show the density of overall population screened in each subgroup by their 
age (which forms the denominator of the probability analysis).
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Table 1
Summary of Characteristics by Age Group Strata Among All Women
All Screened Women (n = 
48,626)
Women Aged ≤35 yrs (n = 
31,578)
Women Aged >35 yrs (n = 
17,048) P
Age 32 (26–39) 27 (24–31) 42 (38–49) <0.001
Education, n (%) <0.001
 Missing 13,055 (26.8) 8620 (27.3) 4435 (26.0)
  Less than high school 15,178 (42.7) 8667 (37.8) 6511 (51.6)
  High school completed 20,393 (57.3) 14,291 (62.2) 6102 (48.4)
Marital status, n (%) <0.001
 Married 41,972 (86.3) 27,491 (87.1) 14,481 (84.9)
 Not married 6654 (13.7) 4087 (12.9) 2567 (15.1)
Occupation, n (%) <0.001
 Missing 16,840 (34.6) 11,149 (35.3) 5691 (33.4)
  House wife 11,412 (35.9) 8046 (39.4) 3366 (29.6)
  Formal sector 6785 (21.3) 4233 (20.7) 2552 (22.5)
  Informal sector 9183 (28.9) 5029 (24.6) 4154 (36.6)
  Other 4406 (13.9) 3121 (15.3) 1285 (11.3)
Income, n (%) <0.001
 Missing 14,387 (29.6) 9577 (30.3) 4810 (28.2)
  Less than K500,000 18,675 (54.5) 12,479 (56.7) 6196 (50.6)
  K500,000 or more 15,564 (45.5) 9522 (43.3) 6042 (49.4)
No. lifetime sexual partners 2 (1–4) 2 (2–3) 2 (1–4) 0.04
 Missing, n (%) 779 (1.6) 465 (1.5) 314 (1.8)
Ever had Pap smear 1212 (2.5) 474 (1.5) 738 (4.3)
Age at sexual debut 18 (16–19) 18 (16–19) 18 (16–20) <0.001
 Missing, n (%) 1567 (3.2) 971 (3.1) 596 (3.5)
No. pregnancies 3 (2–5) 2 (1–4) 5 (3–7) <0.001
 Missing, n (%) 4316 (8.9) 3653 (11.6) 663 (3.9)
Condom use with regular partner, n (%) <0.001
 Missing 4123 (8.5) 2357 (7.5) 1766 (10.4)
  Never 28,688 (64.5) 17,369 (59.4) 11,319 (74.1)
  Ever 15,815 (35.5) 11,852 (40.6) 3963 (25.9)
HIV serostatus, n (%) <0.001
 HIV seropositive 14,153 (29.1) 8269 (26.2) 5884 (34.5)
 HIV seronegative 20,211 (41.6) 14,667 (46.4) 5544 (32.5)
 HIV serostatus unknown 14,262 (29.3) 8642 (27.4) 5620 (33.0)
Cancer case status, n (%)
 Missing 2573 (5.3) 1605 (5.1) 968 (5.7)
  No cancer 45,482 (98.8) 29,747 (99.2) 15,735 (97.9)
  ICC 571 (1.2) 226 (0.8) 345 (2.1)
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Table 2
Summary of Characteristics by Age-Group Strata Among Women With ICC
All Women With ICC (n 
= 571)
Women With ICC Aged 
≤35 yrs (n = 226)
Women With ICC Aged 
>35 yrs (n = 345) P
Age 38 (32–47) 31 (28–33) 44 (39–53) <0.001
Education, n (%) 0.01
 Missing 226 (39.6) 109 (48.2) 117 (33.9)
  Less than high school 188 (54.5) 52 (44.4) 136 (59.6)
  High school completed 157 (45.5) 65 (55.6) 92 (40.4)
Marital status, n (%) 0.54
 Married 527 (92.3) 211 (93.4) 316 (91.6)
 Not married 44 (7.7) 15 (6.6) 29 (8.4)
Occupation, n (%) 0.69
 Missing 278 (48.7) 127 (56.2) 151 (43.8)
  House wife 91 (31.1) 30 (30.3) 61 (31.4)
  Formal sector 54 (18.4) 22 (22.2) 32 (16.5)
  Informal sector 107 (36.5) 34 (34.3) 73 (37.6)
  Other 41 (14.0) 13 (13.1) 28 (14.4)
Income, n (%) 0.90
 Missing 239 (41.9) 113 (50.0) 126 (36.5)
  Less than K500,000 197 (59.3) 66 (58.4) 131 (59.8)
  K500,000 or more 135 (40.7) 47 (41.6) 88 (40.2)
No. lifetime partners, median (IQR) 3 (2–4) 3 (2–4) 2 (1–3) <0.001
 Missing, n (%) 12 (2.1) 4 (1.8) 8 (2.3)
Ever had PAP smear 23 (0.7) 4 (1.8) 19 (5.5) 0.02
Age at sexual debut, median (IQR), yrs 17 (16–19) 17 (16–19) 17.5 (16–19) 0.06
 Missing, n (%) 25 (4.4) 10 (4.4) 15 (4.3)
No. pregnancies, median 4 (3–7) 3 (2–4) 6 (4–8) <0.001
 Missing, n (%) 33 (5.8) 18 (8.0) 15 (4.3)
Condom use with regular partner, n (%) <0.001
 Missing 64 (11.2) 18 (8.0) 46 (13.3)
  Never 353 (69.6) 116 (55.8) 237 (79.3)
  Ever 154 (30.4) 92 (44.2) 62 (20.7)
HIV serostatus, n (%) <0.001
 HIV seropositive 262 (45.9) 129 (57.1) 133 (38.6)
 HIV seronegative 131 (22.9) 41 (18.1) 90 (26.1)
 HIV serostatus unknown 178 (31.2) 56 (24.8) 122 (35.4)
IQR, interquartile range.
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Table 3
Determinants of ICC Among Women Aged ≤35 Years (Crude and Covariate-Adjusted 
Analysis)
Crude Odds Ratio (95% CI) aOR (95% CI)
Age (per 5-yr increase) 2.06 (1.71 to 2.48) 1.68 (1.39 to 2.03)
Education
 Less than high school (ref) 1 1
 High school complete 0.73 (0.51 to 1.03) 0.86 (0.59 to 1.26)
Marital status
 Not married (ref) 1 1
 Married 2.12 (1.25 to 3.57) 2.07 (1.22 to 3.50)
HIV status
 HIV seronegative (ref) 1 1
 HIV seropositive 6.12 (4.29 to 8.74) 4.05 (2.77 to 5.94)
 HIV serostatus unknown 2.30 (1.54 to 3.44) 1.95 (1.30 to 2.92)
No. partners
 1 (ref) 1 1
 2 2.31 (1.77 to 3.02) 1.83 (1.38 to 2.42)
 3 3.75 (2.48 to 5.69) 2.56 (1.66 to 3.97)
 4 4.50 (2.83 to 7.15) 2.87 (1.76 to 4.67)
 5 4.63 (2.90 to 7.37) 2.86 (1.75 to 4.67)
Age of sexual debut, yrs
 20 (ref) 1 1
 16 1.24 (1.02 to 1.52) 1.06 (0.85 to 1.32)
 18 0.98 (0.88 to 1.09) 0.92 (0.82 to 1.03)
No. pregnancies (per 1 child) 1.14 (1.06 to 1.22) 0.96 (0.88 to 1.05)
Condom use with regular partner
 Never (ref) 1 1
 Ever 1.16 (0.88 to 1.54) 0.91 (0.66 to 1.24)
There was little evidence of an interaction between HIV status and age after subsetting to younger women (P = 0.30).
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Table 4
Determinants of ICC Among Women Aged >35 Years (Crude and Covariate-Adjusted 
Analysis)
Crude Odds Ratio (95% CI) aOR (95% CI)
Age (per 5-yr increase) 0.88 (0.71 to 1.08) 1.17 (1.10 to 1.26)
Education
 Less than high school (ref) 1 1
 High school complete 0.77 (0.59 to 1.01) 0.92 (0.68 to 1.26)
Marital status
 Not married (ref) 1 1
 Married 1.85 (1.27 to 2.70) 2.20 (1.50 to 3.23)
HIV status
 HIV seronegative (ref) 1 1
 HIV seropositive 1.47 (1.13 to 1.93) 1.78 (1.35 to 2.36)
 HIV serostatus unknown 1.34 (1.02 to 1.76) 1.23 (0.93 to 1.62)
No. life partners
 1 (ref) 1 1
 2 0.95 (0.80 to 1.12) 1.00 (0.84 to 1.19)
 3 0.91 (0.71 to 1.18) 1.00 (0.76 to 1.30)
 4 0.90 (0.68 to 1.18) 0.99 (0.74 to 1.32)
 5 0.88 (0.67 to 1.16) 0.97 (0.73 to 1.31)
Age of sexual debut, yrs
 20 (ref) 1 1
 16 1.12 (0.93 to 1.35) 1.03 (0.84 to 1.26)
 18 1.12 (1.02 to 1.23) 1.08 (0.97 to 1.19)
No. pregnancies (per 1 child) 1.07 (1.03 to 1.11) 1.02 (0.98 to 1.07)
Condom use with regular partner
 Never (ref) 1 1
 Ever 0.78 (0.60 to 1.03) 0.84 (0.62 to 1.13)
In the multivariable model, there was strong evidence of an interaction between HIV status and age after subsetting to older women (P < 0.01). If 
an interaction term was included in the above model, then the aOR (95% CI) for a woman aged 35 years (as an example) and HIV positive vs. 
negative was 1.39 (0.81 to 2.40). The aOR (95% CI) for a woman aged 35 years and HIV status unknown vs. negative was 1.00 (0.84 to 1.19). For 
every 5-year increase in age, the odds of having ICC decreased 6% (aOR = 0.94; 95% CI: 0.80 to 1.09) for an HIV-positive woman, increased 28% 
(aOR = 1.28; 95% CI: 1.14 to 1.43) for an HIV-negative woman, and increased 23% (aOR = 1.23; 95% CI: 1.13 to 1.34) for a woman with 
unknown HIV status.
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